Keyphrases
Breast Cancer
66%
Chemotherapy
53%
Phase II Study
43%
Phase II Trial
36%
Overall Survival
35%
5-fluorouracil (5-FU)
33%
Tumor
32%
Structuredness
30%
Radiotherapy
30%
Breast Carcinoma
28%
Disease-free Survival
28%
Metastatic Melanoma
26%
Carboplatin
26%
Cyclophosphamide
26%
Ipilimumab
24%
Interleukin-2
24%
Fluorescence Polarization
24%
Breast Cancer Survivors
24%
Placebo-controlled
24%
Melanoma Vaccine
24%
Cisplatin
24%
Adjuvant Chemotherapy
22%
Nuclear factor-κB
22%
Metastatic Breast Cancer
21%
Metastasis
20%
Pancreatic Cancer Cells
20%
Breast
19%
Dacarbazine
18%
Mitoxantrone
18%
Matrix Test
17%
Melanoma
17%
Heavily Pretreated
17%
Vortex
17%
Adaptation
16%
Lymph Node-positive Breast Cancer
16%
PCV Chemotherapy
16%
Anaplastic Astrocytoma
16%
Endometrial Carcinoma
16%
Epirubicin
16%
Strontium-89
16%
Postoperative Radiotherapy
16%
Allogeneic
16%
Bacterial Colony
16%
Lymphocytes
16%
Clinical Oncology
16%
Colonial Expansion
16%
Ovarian Cancer
16%
Methotrexate
16%
Chemotherapy-induced
16%
Polarization Change
16%
Medicine and Dentistry
Breast Cancer
100%
Metastatic Carcinoma
54%
Radiation Therapy
50%
Neoplasm
46%
Malignant Neoplasm
42%
Nodular Melanoma
41%
Lymph Node
38%
Overall Survival
35%
Disease
30%
Recurrent Disease
27%
Fluorouracil
25%
Fluorescence Polarization
24%
Melanoma Vaccine
24%
Cyclophosphamide
24%
Diagnosis
23%
Krukenberg Tumor
23%
Disease Free Survival
23%
Bone Metastasis
21%
Adjuvant Chemotherapy
20%
Lymphocyte
20%
Mitoxantrone
18%
Cancer Cell
18%
Endometrium Carcinoma
16%
Methotrexate
16%
Strontium 89
16%
Dacarbazine
16%
Ipilimumab
16%
Cancer Test
16%
Carcinoma
16%
Clinical Oncology
16%
Hormone Substitution
16%
Placebo
16%
Colposcopy
16%
Glioblastoma
16%
Pancreas Cancer
16%
Kaposi Sarcoma
16%
Adverse Event
16%
Programmed Cell Death
15%
Breast Carcinoma
15%
Folinic Acid
13%
Lomustine
12%
Lymphocyte Activation
12%
CA-125
12%
Cisplatin
11%
Bone Pain
11%
Arm
11%
Gemcitabine
10%
Spontaneous Remission
10%
Procarbazine
10%
Vincristine
10%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
99%
Breast Cancer
52%
Disease
36%
Melanoma
36%
Neoplasm
33%
Fluorouracil
33%
Malignant Neoplasm
31%
Cisplatin
30%
Placebo
29%
Overall Survival
27%
Ovary Carcinoma
26%
Carboplatin
26%
Ipilimumab
24%
Pancreas Cancer
24%
Cyclophosphamide
22%
Recurrent Disease
22%
Disease Free Survival
21%
Metastatic Breast Cancer
20%
Phase II Trials
18%
Mitoxantrone
18%
Nuclear Factor
17%
Epirubicin
16%
Moringa oleifera
16%
Methotrexate
16%
Colorectal Carcinoma
16%
Paclitaxel
16%
Metastatic Melanoma
16%
Folinic Acid
16%
Breast Carcinoma
13%
Adverse Event
12%
Budesonide
12%
Fluoropyrimidine
12%
Ionizing Radiation
12%
Tolerability
12%
Moringa
11%
Herb
11%
Diarrhea
10%
Dacarbazine
9%
Biological Marker
9%
Immunoglobulin Enhancer Binding Protein
9%
Adenocarcinoma
9%
Tamoxifen
9%
Cytotoxic T Lymphocyte Antigen 4
9%
Anti-Inflammatory Drug
9%
Bone Metastasis
9%
Survival Rate
8%
Gastrointestinal Toxicity
8%
Fulvestrant
8%
Corticotropin
8%
Endometrium Carcinoma
8%